By Fineline Cube 
US-based Modella AI, a leader in biomedical artificial intelligence (AI), announced a multi-year collaboration with UK pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN). This strategic partnership grants AstraZeneca access to Modella AI’s advanced multimodal AI foundation models, aiming to accelerate the clinical development of AstraZeneca’s global oncology portfolio.
Collaboration Objectives
AstraZeneca will utilize Modella AI’s platform to enhance its oncology research capabilities. The primary goals include strengthening clinical development, advancing biomarker discovery, and improving patient outcomes.
Integration of AI Models
The two parties will closely collaborate to integrate Modella AI’s AI models into AstraZeneca’s R&D workflows. This integration is expected to enable larger-scale and faster data-driven drug discovery.
Financial Details
No financial details of the collaboration were disclosed.-Fineline Info & Tech